Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets

NCT ID: NCT06932159

Last Updated: 2025-04-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-12-23
• Study Completion Date: 2025-04-08

Brief Summary

An open label, balanced, randomized, single dose, two treatment, two sequence, two period, two way crossover oral bioequivalence study in healthy, adult, human subjects under fasting condition.

Conditions

Type 2 Diabetes Mellitus (T2DM)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Empagliflozin + Linagliptin film-coated tablets

Empagliflozin + Linagliptin 25 mg/5 mg film-coated tablets

Group Type: EXPERIMENTAL

Empagliflozin + Linagliptin film-coated tablets

Intervention Type: DRUG

1 tablet of Empagliflozin + Linagliptin 25 mg/5 mg film-coated tablets

Glyxambi film-coated tablets

Intervention Type: DRUG

1 tablet of Glyxambi 25 mg/ 5 mg film-coated tablets

Glyxambi film-coated tablets

Glyxambi 25 mg/ 5 mg film-coated tablets

Group Type: ACTIVE_COMPARATOR

Empagliflozin + Linagliptin film-coated tablets

Intervention Type: DRUG

1 tablet of Empagliflozin + Linagliptin 25 mg/5 mg film-coated tablets

Glyxambi film-coated tablets

Intervention Type: DRUG

1 tablet of Glyxambi 25 mg/ 5 mg film-coated tablets

Interventions

Empagliflozin + Linagliptin film-coated tablets

1 tablet of Empagliflozin + Linagliptin 25 mg/5 mg film-coated tablets

Intervention Type: DRUG

Glyxambi film-coated tablets

1 tablet of Glyxambi 25 mg/ 5 mg film-coated tablets

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subjects aged between 18 to 45 years (both inclusive).
• Subjects' weight within normal range according to normal values for Body Mass Index (between 18.5 to 30.0 kg/m2) (both inclusive) with minimum of 45 kg weight.
• Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable range.
• Subject with Creatinine Clearance ≥80 ml/min.
• Subjects having clinically acceptable 12-lead electrocardiogram (ECG).
• Subjects having clinically acceptable chest X-Ray (PA view), if taken.
• Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
• Subjects having negative urine alcohol test / breath alcohol test.
• Non-smoker
• Subjects willing to adhere to the protocol requirements and to provide written informed consent.
• For male Subjects:

• Subjects willing to follow approved birth control methods (a double barrier method) for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide, Condom with diaphragm, or abstinence. Subjects willing to refrain from donating sperm during the study period.
• For Female Subjects:

• Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), abstinence, bilateral tubal ligation or double barrier contraception, i.e., condom + diaphragm, condom + spermicidal or foam
• Postmenopausal for at least 1 year, or if less than 1 year, then following acceptable contraceptive measures as mentioned above
• Subjects having negative urine pregnancy test at screening and negative serum β-hCG pregnancy test on admission day of period 01 (only for female subjects).

Exclusion Criteria

• Hypersensitivity to Empagliflozin & Linagliptin or related class of drugs or any of its excipients or heparin.
• History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.
• Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to admission in period 01.
• History or presence of alcoholism or drug abuse.
• History of any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis) History or presence of asthma, urticaria or other significant allergic reactions.
• History or presence of significant gastric and/or duodenal ulceration.
• History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
• History or presence of cancer or basal or squamous cell carcinoma.
• Difficulty with donating blood.
• Difficulty in swallowing solids dosage form like tablets or capsules.
• Use of any prescribed medication or OTC medication including vaccines, vitamins and herbal remedies during last 30 days prior to admission in period 01.
• Major illness within past 3 months.
• Volunteer who have donated blood (1 unit) or participation in a drug research study within past 90 days prior to the first dose of the study drug.
• Consumption of xanthine-containing products, tobacco containing products or alcohol or any alcohol containing products within 48.00 hours prior to admission in period 01.
• Consumption of grapefruit or grapefruit juice containing products within 72.00 hours prior to admission of period 01.
• Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
• History or presence of significant easy bruising or bleeding.
• History or presence of significant recent trauma.
• Subjects who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.
• History of acute conditions with the potential to alter renal function.
• Female subjects who are currently breast feeding.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Humanis Saglık Anonim Sirketi

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Veeda Clinical Research Ltd.

Ahmedabad, Gujarat, India

Countries

India

Other Identifiers

24-VIN-0555

Identifier Type: -

Identifier Source: org_study_id